Myriad Genetics, Inc. (MYGN): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la medicina de precisión, Myriad Genetics, Inc. (MYGN) emerge como una fuerza pionera, transformando las ideas genéticas en soluciones de salud que cambian la vida. Al aprovechar las tecnologías de secuenciación genética de vanguardia y los servicios de diagnóstico integrales, la compañía está a la vanguardia de la evaluación personalizada de riesgos, ofreciendo enfoques innovadores para comprender las predisposiciones genéticas para condiciones críticas como el cáncer. Su innovador modelo de negocio integra investigación científica avanzada, asociaciones estratégicas y soluciones centradas en el paciente, creando un ecosistema único que capacita a los profesionales de la salud y a las personas con conocimiento genético sin precedentes y estrategias médicas proactivas.

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con proveedores de atención médica y hospitales

A partir de 2024, Myriad Genetics ha establecido asociaciones con las siguientes redes de salud:

Socio de atención médica	Enfoque de asociación	Año establecido
Clínica de mayonesa	Colaboración de pruebas genéticas	2019
Memorial Sloan Kettering Cancer Center	Detección genética oncológica	2020
Clínica de Cleveland	Evaluación de riesgos de cáncer hereditario	2021

Asociaciones de investigación con instituciones de investigación académica y médica

Myriad Genetics mantiene colaboraciones de investigación activa con las siguientes instituciones:

• Universidad de Utah (socio de investigación principal)
• Departamento de Genética de la Universidad de Stanford
• Facultad de Medicina de la Universidad Johns Hopkins
• Centro de Investigación de Genética de la Escuela de Medicina de Harvard

Compañías farmacéuticas para pruebas genéticas y desarrollo de fármacos

Asociaciones farmacéuticas clave a partir de 2024:

Compañía farmacéutica	Tipo de colaboración	Valor de asociación estimado
Astrazeneca	Pruebas de oncología de precisión	$ 45 millones
Merck & Co.	Investigación de biomarcadores genéticos	$ 38 millones
Bristol Myers Squibb	Detección genética del cáncer	$ 52 millones

Compañías de seguros para cobertura y reembolso de pruebas genéticas

Asociaciones de seguro para la cobertura de pruebas genéticas:

• UnitedHealthcare
• Himno cruzado
• Cigna
• Aetna

Fabricantes de tecnología y equipos de diagnóstico

Asociaciones técnicas para equipos de diagnóstico:

Socio tecnológico	Equipo/tecnología	Duración de la asociación
Ilumina	Plataformas de secuenciación de próxima generación	5 años
Thermo Fisher Scientific	Instrumentos de análisis genético	4 años
Roche Diagnostics	Sistemas de diagnóstico molecular	6 años

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: actividades clave

Pruebas genéticas y servicios de diagnóstico

Myriad Genetics realiza aproximadamente 250,000 pruebas genéticas anualmente. La cartera de pruebas específica incluye:

Categoría de prueba	Número de pruebas	Ingresos anuales
Detección de cáncer hereditario	125,000	$ 187.4 millones
Pruebas de salud reproductiva	75,000	$ 112.6 millones
Pruebas genéticas de salud mental	50,000	$ 64.3 millones

Investigación y desarrollo genético

Detalles de la inversión de investigación:

• Gastos anuales de I + D: $ 98.7 millones
• Número de proyectos de investigación activos: 42
• Portafolio de patentes: 276 patentes genéticas activas

Detección de medicina de precisión y oncología

Detalles de detección oncológica:

Tipo de detección	Pruebas anuales	Penetración del mercado
Riesgo de cáncer hereditario	95,000	67% del mercado objetivo
Perfil tumoral	45,000	52% de los centros de oncología

Análisis bioinformático y datos

Capacidades de procesamiento de datos:

• Datos genéticos procesados ​​anualmente: 3.2 petabytes
• Algoritmos de aprendizaje automático: 18 modelos patentados
• Infraestructura computacional: 672 servidores informáticos de alto rendimiento

Soporte de ensayos clínicos y soluciones de medicina personalizada

Intermisión del ensayo clínico:

Categoría de prueba	Pruebas activas	Inscripción de participantes
Pruebas de oncología	23	4.750 participantes
Ensayos de salud reproductiva	12	2.300 participantes
Ensayos farmacogenómicos	7	1.100 participantes

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: recursos clave

Tecnologías avanzadas de secuenciación genética

Myriad Genetics utiliza plataformas de secuenciación de próxima generación (NGS) con las siguientes especificaciones:

Tecnología	Capacidad	Rendimiento
Illumina Novaseq 6000	Hasta 6 terabases por carrera	16 mil millones de lecturas por carrera
Secuenciador genético de torrent ion torrent	Secuenciación del panel de genes dirigidos	Hasta 50 millones de lecturas por carrera

Bases de datos genéticas y algoritmos patentados

Composición de base de datos genética:

• Base de datos de variadores genéticos totales: 3.8 millones de variantes genéticas únicas
• Base de datos de predisposición al cáncer: 1.2 millones de mutaciones genéticas relacionadas con el cáncer
• Base de datos de enfermedades hereditarias: más de 500,000 marcadores genéticos clínicamente validados

Experiencia de investigación científica

Composición del equipo de investigación y desarrollo:

Categoría	Número de profesionales
Investigadores de doctorado	87
Asesores genéticos	42
Especialistas en bioinformática	63

Infraestructura de laboratorio especializada

Detalles de las instalaciones de laboratorio:

• Espacio de laboratorio total: 78,000 pies cuadrados
• Instalaciones certificadas por CLIA: 3 centros de prueba primarios
• Capacidad de prueba anual: 500,000 pruebas genéticas

Propiedad intelectual y cartera de patentes

Categoría de patente	Número de patentes	Rango de vencimiento
Métodos de prueba genética	37	2025-2036
Algoritmos de diagnóstico	22	2027-2039
Identificación del marcador genético	15	2026-2033

Myriad Genetics, Inc. (MYGN) - Modelo de negocio: propuestas de valor

Detección temprana de predisposiciones genéticas a enfermedades

Myriad Genetics ofrece pruebas genéticas con las siguientes métricas clave:

Tipo de prueba	Precisión de detección	Volumen de prueba anual
Prueba de cáncer hereditario de BRCA	99.3%	175,000 pruebas
Prueba de riesgo de cáncer de próstata	97.6%	85,000 pruebas

Evaluación de riesgos personalizada para el cáncer y las afecciones hereditarias

Los servicios de evaluación de riesgos genéticos incluyen:

• Detección de cáncer de seno y ovario hereditario
• Evaluación del riesgo genético del cáncer colorrectal
• Evaluación de riesgo genético de enfermedades cardiovasculares

Estrategias mejoradas de tratamiento del paciente

El enfoque de medicina de precisión de Myriad proporciona:

Segmento de tratamiento	Número de terapias dirigidas	Impacto del paciente
Medicina de precisión de oncología	42 terapias dirigidas	63,000 pacientes anualmente
Prueba farmacogenómica	26 interacciones de medicamentos	48,000 pacientes anualmente

Servicios integrales de detección genética

La cartera de detección incluye:

• Detección de cáncer hereditario: 8 paneles genéticos diferentes
• Evaluación de riesgo genético prenatal
• Diagnóstico genético de enfermedades raras

Información de diagnóstico avanzada para proveedores de atención médica

Capacidades de diagnóstico:

Categoría de diagnóstico	Número de marcadores genéticos	Tasa de servicios públicos
Diagnóstico oncológico	1,400+ marcadores genéticos	92% de utilidad clínica
Detección de enfermedades hereditarias	1.100+ marcadores genéticos	88% de utilidad clínica

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: relaciones con los clientes

Consultas directas con consejeros genéticos

Myriad Genetics proporciona Servicios de asesoramiento genético 1 a 1 con consejeros profesionales en múltiples canales.

Tipo de consulta	Duración promedio	Volumen anual
Consultas telefónicas	45 minutos	12,500 sesiones
Consultas de video	60 minutos	8.750 sesiones
Consultas en persona	90 minutos	3,750 sesiones

Portales de pacientes y sistemas de apoyo en línea

Plataformas digitales que ofrecen características integrales de participación del paciente.

• MyRisk Portal Active Usuarios: 65,400
• Cumplimiento de la privacidad de datos del paciente: HIPAA 100%
• Interacciones del portal anual: 425,000

Educación profesional médico continuo

Myriad ofrece programas de capacitación especializados para profesionales de la salud.

Programa educativo	Participantes anuales	Horas de programa
Oncología entrenamiento genético	2.350 profesionales	12 horas
Asesoramiento genético reproductivo	1.875 profesionales	8 horas

Comunicación de riesgo genético personalizado

Evaluación de riesgos individualizada y estrategias de comunicación.

• Informes de riesgo personalizados generados: 87,500 anuales
• Precisión de comunicación de riesgos: 98.3%
• Complejidad promedio de informes: 12 marcadores genéticos

Interfaces de tecnología de salud digital

Plataformas tecnológicas avanzadas para la interacción paciente y profesional.

Interfaz tecnológica	Base de usuarios	Interacciones anuales
Aplicación móvil	42,600 usuarios	315,000 interacciones
Portal web	93,500 usuarios	625,000 interacciones

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: canales

Ventas directas a proveedores de atención médica

Myriad Genetics utiliza una fuerza de ventas directa dirigida a oncólogos, ginecólogos y asesores genéticos. A partir de 2024, la compañía mantiene un equipo de ventas dedicado de 185 representantes de ventas directas.

Canal de ventas	Número de representantes	Especialidades objetivo
Ventas oncológicas	95	Genética del cáncer
Ventas a la salud de las mujeres	65	Salud reproductiva
Asesoramiento genético especializado	25	Pruebas genéticas complejas

Plataformas de pruebas genéticas en línea

Myriad opera una plataforma en línea integral para servicios de pruebas genéticas con el siguiente alcance digital:

• Usuarios de plataforma digital: 412,000 usuarios únicos en 2024
• Tasa de pedido de pruebas en línea: 37% de las pruebas genéticas totales
• Compromiso promedio de la plataforma digital: 22 minutos por sesión

Conferencia médica y mercadeo profesional de redes

La compañía invierte significativamente en la comercialización de redes profesionales a través de conferencias médicas y eventos profesionales.

Canal de marketing	Inversión anual	Número de eventos
Conferencias médicas nacionales	$ 3.2 millones	48 conferencias
Simposios profesionales regionales	$ 1.5 millones	76 simposios

Servicios de asesoramiento genético de telemedicina

Myriad ofrece servicios remotos de asesoramiento genético con las siguientes métricas:

• Consultas totales de telemedicina en 2024: 24,700
• Duración de consulta promedio: 47 minutos
• Tasa de satisfacción de la plataforma de asesoramiento digital: 92%

Redes de proveedores de seguros de salud

Myriad mantiene asociaciones extensas con proveedores de seguros de salud:

Red de seguros	Porcentaje de cobertura	Tasa de reembolso
Proveedores de seguros nacionales	87%	$ 1,245 por prueba genética
Redes de seguros regionales	63%	$ 980 por prueba genética

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: segmentos de clientes

Oncología pacientes y riesgo de cáncer individuos

A partir de 2024, Myriad Genetics se dirige a aproximadamente 500,000 pacientes anuales de pruebas genéticas para el riesgo de cáncer hereditario.

Segmento de paciente	Volumen de prueba anual	Costo de prueba promedio
Riesgo de cáncer de seno	250,000	$1,995
Riesgo de cáncer de ovario	75,000	$2,250
Riesgo de cáncer de próstata	100,000	$1,750
Riesgo de cáncer de colon	75,000	$1,500

Profesionales de la salud y médicos

Myriad Genetics atiende a aproximadamente 85,000 proveedores de atención médica activos en todo el país.

• Oncólogos: 35,000 profesionales
• Practicantes de familia: 25,000 profesionales
• Ginecólogos: 15,000 profesionales
• Urólogos: 10,000 profesionales

Centros de asesoramiento genético

La compañía apoya a 2.300 centros de asesoramiento genético en los Estados Unidos.

Tipo central	Número de centros	Volumen de referencia anual
Con sede en el hospital	750	45,000
Clínicas independientes	1,100	35,000
Centros médicos académicos	450	20,000

Instituciones de investigación

Myriad Genetics colabora con 650 instituciones de investigación a nivel mundial.

• Centros de investigación académica: 350
• Laboratorios de investigación farmacéutica: 180
• Instalaciones de investigación gubernamental: 120

Consumidores individuales que buscan ideas genéticas

El segmento de prueba genética directa al consumidor alcanza aproximadamente 75,000 individuos anualmente.

Categoría de consumidor	Volumen de prueba anual	Precio de prueba promedio
Riesgo de salud personal	45,000	$599
Análisis de ascendencia y rasgos	30,000	$399

Myriad Genetics, Inc. (MYGN) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Myriad Genetics reportó gastos de I + D de $ 135.4 millones, lo que representa el 22.4% de los ingresos totales.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 135.4 millones	22.4%
2022	$ 126.7 millones	20.9%

Costos operativos de laboratorio

Los gastos operativos anuales de laboratorio para Myriad Genetics en 2023 totalizaron aproximadamente $ 87.6 millones.

• Costos de mantenimiento de la instalación: $ 22.3 millones
• Depreciación del equipo: $ 18.5 millones
• Suministros de laboratorio: $ 29.8 millones
• Gastos de personal y personal: $ 17 millones

Mantenimiento de la infraestructura tecnológica

Los costos de mantenimiento de la infraestructura tecnológica para 2023 fueron de $ 43.2 millones.

Componente de infraestructura	Costo anual
Sistemas de TI	$ 18.7 millones
Computación en la nube	$ 12.5 millones
Ciberseguridad	$ 6.2 millones
Licencia de software	$ 5.8 millones

Inversiones de ensayos clínicos

Las inversiones en ensayos clínicos para 2023 ascendieron a $ 64.9 millones.

• Pruebas de oncología: $ 32.4 millones
• Investigación de pruebas genéticas: $ 21.5 millones
• Estudios de enfermedades raras: $ 11 millones

Gastos de ventas y marketing

Los gastos de ventas y marketing para 2023 fueron de $ 92.3 millones.

Canal de marketing	Gasto anual
Equipo de ventas directas	$ 45.6 millones
Marketing digital	$ 22.7 millones
Patrocinio de conferencias y eventos	$ 14.2 millones
Materiales promocionales	$ 9.8 millones

Myriad Genetics, Inc. (MYGN) - Modelo de negocios: flujos de ingresos

Tarifas de servicio de pruebas genéticas

Para el año fiscal 2023, Myriad Genetics informó que las tarifas de servicio de pruebas genéticas por un total de $ 775.3 millones. Los principales servicios de prueba genética de la compañía incluyen:

• Pruebas de cáncer hereditario
• Pruebas de salud prenatal y reproductiva
• Pruebas genéticas de salud mental

Categoría de prueba	Ingresos (2023)
Pruebas de cáncer hereditario	$ 456.2 millones
Prueba prenatal	$ 218.7 millones
Pruebas genéticas de salud mental	$ 100.4 millones

Ventas de pruebas de diagnóstico

Las ventas de pruebas de diagnóstico para Myriad Genetics en 2023 alcanzaron $ 632.1 millones. La cartera de diagnóstico de la compañía incluye:

• Pruebas de tumores precisas
• Paneles de diagnóstico molecular
• Pruebas de evaluación de riesgos genéticos especializados

Categoría de prueba de diagnóstico	Ingresos (2023)
Pruebas de tumores precisas	$ 347.6 millones
Paneles de diagnóstico molecular	$ 184.5 millones
Evaluación de riesgos genéticos	$ 100.0 millones

Colaboraciones de investigación farmacéutica

Los ingresos por colaboración de investigación farmacéutica para 2023 totalizaron $ 87.5 millones. Las asociaciones de investigación clave incluyen colaboraciones con:

• Merck & Co.
• Astrazeneca
• Bristol Myers Squibb

Reembolsos de seguros

Los reembolsos de seguros para pruebas genéticas y de diagnóstico en 2023 ascendieron a $ 412.6 millones. Desglose de reembolso:

Categoría de seguro	Cantidad de reembolso (2023)
Seguro privado	$ 276.4 millones
Seguro médico del estado	$ 86.2 millones
Seguro de enfermedad	$ 50.0 millones

Servicios de consulta de medicina de precisión

Los servicios de consulta de medicina de precisión generaron $ 55.2 millones en ingresos para 2023. Los servicios incluyen:

• Asesoramiento genético
• Recomendaciones de tratamiento personalizadas
• Apoyo a la decisión clínica

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Value Propositions

You're looking at the core offerings Myriad Genetics, Inc. is putting forward to the market as of late 2025. These are the specific problems they solve for their customers-patients, providers, and pharma partners.

Comprehensive hereditary cancer risk assessment (MyRisk with RiskScore)

This offering focuses on assessing hereditary cancer risk across eleven cancer types, including breast, ovarian, and prostate. The RiskScore component adds a polygenic risk score layer to the traditional single-gene testing.

• MyRisk with RiskScore testing volume in oncology grew 14% year-over-year in the second quarter of 2025.
• Hereditary cancer testing revenue in Oncology grew 9% year-over-year in the second quarter of 2025.
• Hereditary cancer testing volume in Oncology grew 11% year-over-year in the third quarter of 2025.
• MyRisk affected test volume saw 11% year-over-year growth in the first quarter of 2025.
• Hereditary cancer testing revenue for the unaffected population increased 4% year-over-year in the third quarter of 2025.

Personalized psychotropic medication selection guidance (GeneSight)

GeneSight helps guide prescribing decisions for mental health medications based on a patient's genetic profile. This value proposition has faced recent headwinds, mainly from payer coverage changes.

• GeneSight test revenue was reported at $38.7 million for the third quarter of 2025.
• GeneSight test volume still managed to grow 8% year-over-year in the third quarter of 2025.
• Pharmacogenomics revenue saw a 20% fall in the first quarter of 2025, largely due to UnitedHealthcare discontinuing coverage.

Non-invasive prenatal screening and expanded carrier screening (Foresight, Prequel)

This area delivers insights for prenatal care, including expanded carrier screening. The Prequel test offers an early gestational age window for results.

• The Prequel test delivers critical insights at 8 week gestational age, compared to 10 to 12 weeks for other available tests.
• Prenatal testing revenue grew 7% year-over-year in the second quarter of 2025.
• In the first quarter of 2025, Foresight and Prequel prenatal tests achieved 15% revenue growth and 10% volume growth.

Prognostic information for prostate cancer treatment (Prolaris)

Prolaris provides prognostic information to help guide treatment decisions for prostate cancer patients, aligning with NCCN guidelines.

• Prolaris test revenue grew 4% year-over-year in the second quarter of 2025.
• Prolaris testing revenue grew 3% year-over-year in the third quarter of 2025.
• Revenue for Prolaris decreased 2% year-over-year in the first quarter of 2025.

Companion diagnostic (CDx) services for pharmaceutical clinical trials

Myriad Genetics, Inc. offers services to pharmaceutical partners to develop and provide CDx testing solutions, often involving liquid biopsy technology for therapy selection.

• In September 2025, Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) testing solution.
• Existing CDx offerings include BRACAnalysis CDx and MyChoice CDx.

Here's a quick look at how the segments contributed to the overall financial picture as of the third quarter of 2025, which informed the raised full-year guidance.

Metric	Value (Latest Reported Period)	Period End Date
Total Revenue	$205.7 million	Q3 2025
Oncology Segment Revenue	$85.5 million	Q2 2025
Women's Health Segment Revenue	$89.8 million	Q2 2025
GeneSight Test Revenue	$38.7 million	Q3 2025
Adjusted Gross Margin	69.9%	Q3 2025
Adjusted EPS	$0.00	Q3 2025
FY 2025 Revenue Guidance (Raised Range)	$818 - $828 million	Full Year 2025

The company's ability to maintain a strong gross margin, reaching 71.2% in Q2 2025, shows operational discipline supporting these value propositions. Also, the adjusted EPS for Q2 2025 was $0.05, beating expectations.

The overall strategy is to accelerate growth by focusing on the Cancer Care Continuum, which directly supports the MyRisk and Prolaris value propositions. Finance: review the impact of the new $200 million term loan secured on July 31, 2025, on Q4 cash flow projections by next Tuesday.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Customer Relationships

Myriad Genetics, Inc. maintains a high-touch engagement model with clinicians, supported by a substantial internal commercial structure. As of February 2025, the U.S. sales force was comprised of approximately 500 individuals across dedicated sales channels. The company is actively working to enhance its commercial capabilities and the overall customer digital experience to better serve the Cancer Care Continuum (CCC) market opportunity.

Digital integration is a key focus for streamlining clinician interaction. Myriad Genetics expects its full oncology portfolio of germline and tumor genomic tests to be fully integrated with both Flatiron's OncoEMR and Epic cloud-based platforms later in 2025. This integration is designed to create an end-to-end workflow solution allowing clinicians to order, receive, and review Myriad test results directly within their primary platforms. This deployment of electronic medical records (EMR) solutions was cited as a factor in the stable volume for hereditary cancer testing in the unaffected population during the first quarter of 2025.

Support for patients remains a component of the relationship strategy, explicitly including patient financial assistance programs. Furthermore, Myriad Genetics continues to engage with the genetic counseling community, presenting research at the National Society of Genetic Counselors (NSGC) 44th Annual Conference in November 2025, aiming to help make genetic testing more accessible for all patients.

Strategic, long-term relationships with Biopharma partners are leveraged to unlock new growth drivers, focusing on Biopharma service synergies. A significant development in late 2025 was the strategic collaboration entered into in September 2025 with SOPHiA GENETICS to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. Additionally, the company entered into an exclusive license agreement in February 2025 with PATHOMIQ to add its AI technology platform for prostate cancer, complementing the Prolaris Prostate Cancer Prognostic test.

Key metrics reflecting the scale and satisfaction within these customer relationships include:

• Net Promoter Score (NPS) consistently maintained above 70 since 2022.
• The company services over 45,000+ active ordering healthcare providers (data as of fourth quarter, 2023).
• The U.S. sales force size was approximately 500 individuals as of February 2025.

The following table summarizes key quantitative aspects related to Myriad Genetics, Inc.'s customer engagement as of recent 2025 reporting periods:

Relationship Metric Category	Specific Data Point	Reported Value (as of late 2025)
Clinician Reach	U.S. Dedicated Sales Force Size	Approximately 500 individuals
Digital Workflow	EMR Integration Target Platforms	Flatiron OncoEMR and Epic
Digital Workflow	EMR Full Integration Expectation	Later in 2025
Customer Satisfaction	Net Promoter Score (NPS)	Consistently above 70
Partnerships	New CDx Collaboration Announced	SOPHiA GENETICS (September 2025)
Partnerships	AI Technology License Agreement	PATHOMIQ (February 2025)

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Channels

You're looking at how Myriad Genetics, Inc. gets its molecular diagnostic tests into the hands of the clinicians and patients who need them. The channel strategy is a mix of traditional, high-touch sales and modern digital integration, which is key to navigating the complex reimbursement landscape.

The direct sales force remains a cornerstone. As of February 2025, this team comprised approximately 500 individuals in the U.S.. These representatives are focused on deep education and relationship building directly with ordering specialists. To support this, Myriad Genetics is actively investing in commercial capabilities; for instance, they are investing over $35 million in enhancing these channels and expanding the sales team as they head into 2026.

Integration with the provider workflow is another major channel focus. Myriad Genetics is expanding its footprint in Electronic Medical Records (EMR) systems across hospital systems and large clinic networks. This is designed to make ordering and reporting seamless right where the doctor works. You can see this effort reflected in the Women's Health segment; in the second quarter of 2025, hereditary cancer testing volume for the unaffected population grew by 3% year-over-year, partly due to expanding these EMR solutions.

Here's a snapshot of the scale of these channel relationships as of the latest data:

Channel Metric	Value/Amount	Context/Date
U.S. Direct Sales Force Size	Approximately 500 individuals	As of February 2025
Total Payer Contracts	Over 3000	Reported
Testing Volume Covered by Insurance	Approximately 90%	In 2024
Investment in Commercial Channel Expansion	Over $35 million	Planned for 2026 growth
GeneSight Revenue (Q3 2025)	$38.7 million	Reflecting payer coverage headwinds

Navigating third-party payors is critical for access and revenue. Myriad Genetics maintains contracts with over 3000 payers, which is how they secure broad test coverage. However, this channel faces immediate risk; the discontinuation of coverage for the GeneSight test by UnitedHealthcare, effective in the first quarter of 2025, created a significant headwind. Still, other areas show payer progress; prenatal testing revenue in the second quarter of 2025 grew by 7% year-over-year, driven by expanding payer coverage for the Foresight Expanded Carrier Screen.

For certain tests, Myriad Genetics uses direct-to-patient marketing to build awareness and drive provider orders. This is a growing area, as they are increasing digital marketing efforts. However, this approach shows mixed results depending on the product. For example, in the third quarter of 2025, prenatal volume decreased by 3% year-over-year, largely driven by lower demand for the SneakPeek test. The company is definitely working to optimize this direct outreach.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Customer Segments

The customer segments for Myriad Genetics, Inc. are clearly delineated across clinical specialties, each served by specific diagnostic offerings.

Oncology: Physicians and patients with cancer or high-risk for hereditary cancer

This segment is served by hereditary cancer testing, including the MyRisk Hereditary Cancer Test, and companion diagnostic tests like BRACAnalysis CDx and MyChoice CDx.

The performance metrics for the Oncology segment show growth in testing volume:

Metric	Period Ended Q2 2025	Period Ended Q3 2025
Revenue	$85.5 million	$81.8 million
Hereditary Cancer Testing Volume Growth (YoY)	10%	11%
MyRisk with RiskScore Testing Volume Growth (YoY)	14%	13%

The Prolaris Prostate Cancer Prognostic Test also targets this group:

• Prolaris test revenue grew 4% year-over-year in the second quarter of 2025.
• Prolaris testing revenue grew 3% year-over-year in the third quarter of 2025.

Myriad Genetics plans to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first quarter of 2026.

Women's Health: OB/GYNs, maternal-fetal medicine specialists, and pregnant patients

This segment focuses on prenatal and carrier screening tests, including Foresight Carrier Screen and Prequel Prenatal Screen.

Revenue performance for Women's Health:

Metric	Period Ended Q1 2025	Period Ended Q2 2025
Prenatal Testing Revenue	$55 million	$89.8 million (Segment Revenue)
Prenatal Testing Revenue Growth (YoY)	11%	7%
Prenatal Volume Change (YoY)	Not specified	Decreased 8% (Q2 2025 total prenatal volume vs prior year)

The third quarter of 2025 showed Prenatal testing revenue growth of 2% year-over-year, with volume decreasing 3% year-over-year.

The company launched the Prequel®Early Gestational Age test in the mid-fourth quarter of 2024, showing positive early adoption in the first quarter of 2025.

Mental Health: Psychiatrists and primary care physicians prescribing psychotropics

The primary offering for this segment is the GeneSight test for pharmacogenomics.

This segment faced significant headwinds:

• First quarter 2025 Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare reducing coverage of GeneSight.
• GeneSight test revenue was $37.8 million in the second quarter of 2025.
• Pharmacogenomics revenue decreased by $5.2 million in Q2 2025 due to a 16% decrease in average revenue per test, impacted by the UnitedHealthcare coverage change.
• GeneSight test volume in the second quarter of 2025 grew 5% year-over-year.

Pharmaceutical and Biopharma companies for CDx development services

Myriad Genetics, Inc. supports Biopharma partners with companion diagnostic (CDx) development and customized clinical trial testing.

The company has supported hundreds of clinical trials.

In September 2025, Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

The company expects to leverage strategic partnerships and Biopharma service synergies to unlock new growth drivers.

Myriad Genetics operates in the Global Companion Diagnostics Market, which was valued at USD $7.2 billion in 2024.

The company serves more than 51,000 physicians across its specialties as of August 2025.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the ledger for Myriad Genetics, Inc. (MYGN) as of late 2025. It's a mix of direct lab costs, heavy commercial spend, and managing a new debt load. Honestly, for a diagnostics company, the cost structure is dominated by the lab work and getting those tests into the hands of clinicians.

The direct costs tied to running the tests, which we call Cost of Revenue, were reported at $61.9 million for the third quarter of 2025. This figure is key because it directly drives the gross margin, which management noted was a strong 69.9% for that same quarter. That margin tells you the core science and lab process is efficient, which is definitely a positive sign.

When we look at the operating expenses, the commercial engine is clearly the biggest driver. Sales and Marketing expenses represented 34.5% of the total Q3 2025 revenue of $205.7 million. Also, Research and Development (R&D) investment, which fuels future growth pipelines like the planned AI-enabled prostate cancer test launch in 2026, consumed 13.7% of that revenue base.

To give you a clearer picture of the operating spend, here is how the major components stack up for Q3 2025. We can see that the specified costs align almost exactly with the reported total operating expenses.

Expense Category	Reported Value/Percentage (Q3 2025)	Calculated Dollar Amount (Approx.)
Cost of Revenue	$61.9 million	$61.9 million
Sales and Marketing (as % of Revenue)	34.5%	Approx. $71.0 million
Research and Development (as % of Revenue)	13.7%	Approx. $28.2 million
General and Administrative (G&A)	$67.9 million	$67.9 million
Total Specified Operating Costs	N/A	Approx. $167.1 million
Total Reported Operating Expenses	$167.1 million	$167.1 million

The General and Administrative (G&A) costs were a fixed-looking $67.9 million in the quarter. It's important to note that management has been focused on disciplined cost management, as the total operating expenses of $167.1 million actually decreased year-over-year by $2.7 million. That discipline helps push the adjusted EBITDA to a positive $10.3 million, even with the heavy commercial spend.

Finally, you can't ignore the balance sheet costs impacting cash flow. Myriad Genetics entered a new $200 million term loan facility in July 2025. Servicing this debt is a fixed commitment that needs to be factored into ongoing cash planning, separate from the operational P&L line items. You have to account for the interest and principal payments on that facility moving forward.

Here are the key cost drivers you need to keep an eye on:

• Cost of Revenue: $61.9 million in Q3 2025.
• Sales and Marketing: Accounted for 34.5% of revenue.
• R&D Investment: Took up 13.7% of revenue.
• G&A Overhead: A flat $67.9 million for the quarter.
• New Debt Obligation: Servicing the $200 million term loan.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Revenue Streams

You're looking at how Myriad Genetics, Inc. (MYGN) brings in the cash, which is all about the tests they sell. For the full fiscal year 2025, the company reaffirmed its revenue guidance to be in the range of $818 million - $828 million. That guidance was reiterated following solid execution in the third quarter of 2025, even though consolidated revenue for that quarter was reported at $205.7 million, a 4% decrease year-over-year, but flat when excluding certain headwinds.

The revenue streams are clearly segmented by their primary diagnostic areas. Hereditary Cancer testing, driven by MyRisk, remains a cornerstone, but you see significant contributions from Prenatal and Pharmacogenomics as well. Honestly, the mix shows a strategic focus on the Cancer Care Continuum, but Women's Health and Mental Health still provide substantial top-line support. It's all about getting tests ordered and paid for.

Here's a look at the revenue generated by the key testing categories for the third quarter of 2025:

• Hereditary Cancer testing (MyRisk) brought in $93.0 million.
• Prenatal testing (Foresight, Prequel) generated $44.5 million.
• Pharmacogenomics testing (GeneSight) accounted for $38.7 million.
• Tumor Profiling (Prolaris, myChoice CDx) contributed $29.5 million.

The growth story is often in the volume, not just the dollars. For instance, hereditary cancer testing volume in Oncology grew 9% year-over-year in Q3 2025, and GeneSight test volume was up 8% year-over-year. Still, average revenue per test across the board saw a 7% drop in Q3 2025, which pressures the top line even when volumes are up.

To map out the key revenue drivers from the third quarter of fiscal 2025, this table breaks down the reported segment contributions:

Revenue Stream Category	Product Focus	Q3 2025 Revenue Amount
Hereditary Cancer Testing (Oncology Focus)	MyRisk (Oncology)	$93.0 million
Women's Health Testing	Hereditary Cancer (Unaffected Population)	$44.5 million
Pharmacogenomics	GeneSight	$38.7 million
Tumor Profiling	Prolaris, myChoice CDx	$29.5 million

You can see the Women's Health business, which includes prenatal and hereditary cancer testing for the unaffected population, delivered total revenue of $85.2 million in Q3 2025. The Oncology business, focused on hereditary cancer and Prolaris, brought in $81.8 million in the same period. The difference between the sum of the four listed streams and the total revenue reflects other smaller streams, like Mental Health revenue (which includes GeneSight) and any revenue from divested assets or partnerships not explicitly broken out in the prompt's required list. Finance: draft 13-week cash view by Friday.